H.R. 1730 117th Congress
Speeding Therapy Access Today Act of 2021
- Health
- Sponsor: Rep. Bilirakis, Gus M. [R-FL-12]
- Congress.gov ↗
Latest action, Mar 10, 2021: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
40 cosponsors
Sponsored by Rep. Bilirakis, Gus M. [R-FL-12] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
25 D · 15 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
FAEGRE DRINKER BIDDLE & REATH LLP
8 reports
8 reports
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
7 reports
6 reports
TRAVERE THERAPEUTICS
ALSTON & BIRD LLP
6 reports
5 reports
AEGLEA BIOTHERAPEUTICS, INC.
THE KPM GROUP DC LLC
4 reports
4 reports
4 reports
4 reports
CHIESI USA, INC.
THE KPM GROUP DC LLC
3 reports
ULTRAGENYX PHARMACEUTICAL
THE KPM GROUP DC LLC
3 reports
2 reports
All 25 of 26 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) | FAEGRE DRINKER BIDDLE & REATH LLP | 8 | $20K | Q1 2021 | Q3 2022 | yes |
| TRAVERE THERAPEUTICS | 8 | $1.3M | Q1 2021 | Q3 2022 | yes | |
| RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) | 7 | $140K | Q4 2021 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 6 | $7.2M | Q4 2021 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 5 | $5.8M | Q2 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 5 | $34.7M | Q2 2021 | Q3 2022 | yes | |
| AEGLEA BIOTHERAPEUTICS, INC. | THE KPM GROUP DC LLC | 4 | $110K | Q1 2021 | Q2 2022 | yes |
| GENENTECH INC | 4 | $8.8M | Q1 2022 | Q3 2022 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $4.7M | Q1 2021 | Q2 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 4 | $3.9M | Q1 2022 | Q3 2022 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 3 | $9.5M | Q1 2022 | Q3 2022 | yes | |
| CHIESI USA, INC. | THE KPM GROUP DC LLC | 3 | $0 | Q4 2021 | Q1 2022 | yes |
| ULTRAGENYX PHARMACEUTICAL | THE KPM GROUP DC LLC | 3 | $145K | Q1 2021 | Q3 2021 | yes |
| ALEXION PHARMACEUTICALS, INC. | 2 | $430K | Q2 2021 | Q3 2021 | yes | |
| HARMONY BIOSCIENCES | 2 | $500K | Q4 2022 | Q3 2022 | yes | |
| HARMONY BIOSCIENCES | THORN RUN PARTNERS | 2 | $0 | Q4 2022 | Q3 2022 | yes |
| HARMONY BIOSCIENCES, LLC | JEFFREY J. KIMBELL & ASSOCIATES, INC. | 2 | $0 | Q4 2022 | Q3 2022 | yes |
| HARMONY BIOSCIENCES, LLC | RAMPY NORTHRUP LLC | 2 | $0 | Q4 2022 | Q3 2022 | yes |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 1 | $830K | Q1 2022 | Q1 2022 | yes | |
| INOVIO PHARMACEUTICALS, INC. | 1 | $140K | Q2 2022 | Q2 2022 | yes | |
| ORPHAZYME US, INC. | THE KPM GROUP DC LLC | 1 | $45K | Q1 2021 | Q1 2021 | yes |
| REGENXBIO | 1 | $150K | Q1 2022 | Q1 2022 | yes | |
| SANGAMO THERAPEUTICS, INC | THE KPM GROUP DC LLC | 1 | $27K | Q1 2021 | Q1 2021 | — |
| UPS (UNITED PARCEL SERVICE) | 1 | $4.3M | Q1 2022 | Q1 2022 | yes |